Affordable Access

Access to the full text

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

Authors
  • Tanaka, Yoshiya1
  • Smolen, Josef S.2
  • Jones, Heather3
  • Szumski, Annette4
  • Marshall, Lisa3
  • Emery, Paul5
  • 1 University of Occupational and Environmental Health, Japan, The First Department of Internal Medicine, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu, 807-8555, Japan , Kitakyushu (Japan)
  • 2 Medical University of Vienna, Vienna, Austria , Vienna (Austria)
  • 3 Pfizer, Collegeville, PA, USA , Collegeville (United States)
  • 4 Syneos Health, Princeton, NJ, USA , Princeton (United States)
  • 5 University of Leeds, Leeds Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK , Leeds (United Kingdom)
Type
Published Article
Journal
Arthritis Research & Therapy
Publisher
BioMed Central
Publication Date
Jul 05, 2019
Volume
21
Issue
1
Identifiers
DOI: 10.1186/s13075-019-1937-4
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundBiologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawal of the bDMARD. Results from published studies indicate that some patients will maintain remission; however, others will flare. We analyzed data from three etanercept down-titration studies in patients with RA to determine what extent of remission provides the greatest predictability of maintaining remission following dose reduction or discontinuation.MethodsPatients with moderate to severe RA from the PRESERVE, PRIZE, and Treat-to-Target (T2T) randomized controlled trials were included. We determined the proportion of patients achieving remission with etanercept at the last time point in the induction period, and sustained remission (last two time points), according to the Disease Activity Score 28-joints (DAS28), the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean criteria, and the clinical disease activity index (CDAI). We also calculated the proportion achieving DAS28 deep remission (DAS28 ≤ 1.98), sustained deep remission (last two time points), and low disease activity (LDA), and LDA according to the CDAI. Then, we evaluated whether they maintained remission or LDA following etanercept dose reduction or withdrawal.ResultsPatients achieving sustained and/or deep remission were more likely than patients achieving remission or LDA to maintain remission/LDA after etanercept dose reduction or withdrawal. In PRESERVE, the proportions of patients with DAS28 sustained deep remission, deep remission, sustained remission, remission, and LDA who maintained remission following etanercept dose reduction were 81%, 67%, 58%, 56%, and 36%, respectively, P < 0.001 for trend. In PRESERVE, this trend was significant when etanercept was discontinued and when ACR/EULAR Boolean and CDAI remission criteria were used. Although some sample sizes were small, the PRIZE and T2T studies also demonstrated response trends according to ACR/EULAR Boolean and CDAI remission criteria, and T2T demonstrated response trends according to DAS28.ConclusionsThese results suggest that patients achieving disease control according to a stringent definition, such as sustained ACR/EULAR Boolean or CDAI remission, or a new definition of sustained deep remission by DAS28, have a higher probability of remaining in remission or LDA following etanercept dose reduction or withdrawal.Trial registrationPRESERVE: ClinicalTrials.gov identifier: NCT00565409, registered 30 November 2007; PRIZE: ClinicalTrials.gov identifier: NCT00913458, registered 4 June 2009; T2T: ClinicalTrials.gov identifier: NCT01578850, registered 17 April 2012

Report this publication

Statistics

Seen <100 times